Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00408434 · ClinicalTrials.gov registry record · Phase 1
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
A Phase 1 study of Neoplasm, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT00408434: Completed Phase 1 study of Neoplasm, sponsored by Daiichi Sankyo.
NCT00408434 is a Phase 1 study of Neoplasm that has completed, run by Daiichi Sankyo. The registered enrollment target is 32 participants, below the 199-participant average among 11 other Neoplasm trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00408434, a Phase 1 study of Neoplasm, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.
Primary Outcome
Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions). Objective response rate was defined as the sum of all CRs and PRs.
Conditions Studied
Interventions
- DRUG CS-7017
Study Locations (2)
District of Columbia
- - Washington D.C.
Massachusetts
- - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
What the finished NCT00408434 record still lists
NCT00408434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 199-participant average among 11 other Neoplasm trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which CS-7017 is the first listed.
NCT00408434 reports a single indexed study location in District of Columbia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00408434 about?
NCT00408434 is a clinical study titled "Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer". An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.
What is the current status of trial NCT00408434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-11. Estimated completion is 2010-02.
What conditions does trial NCT00408434 study?
This clinical trial studies the following conditions: Neoplasm.
What interventions are being tested in trial NCT00408434?
The interventions under investigation include: CS-7017 (DRUG).
Who is sponsoring clinical trial NCT00408434?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00408434 being conducted?
This trial has 2 study locations across District of Columbia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00408434's enrollment target sits among peer trials
32 9th of 11 higher than 3 of 11 other Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study of LY2835219 in Participants With Cancer
COMPLETED · Phase 1
-
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
COMPLETED · Phase 1
-
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
COMPLETED · Phase 1
-
A Study of Galunisertib on the Immune System in Participants With Cancer
COMPLETED · Phase 1
-
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia